EXHIBIT 99.1 WESTLAKE CHEMICAL PARTNERS LP Contact—(713) 585-2900 Investors—Steve Bender Media—L. Benjamin Ederington Westlake Chemical Partners LP Announces Fourth Quarter and Full Year 2025 Results HOUSTON--(BUSINESS WIRE)--Westlake Chemical Partners LP (NYSE: WLKP) (the "Partnership") today reported net income attributable to the Partnership in the fourth quarter of 2025 of $14.5 million, or $0.41 per limited partner unit, which was relatively in line with fourth quarter 2024 net income of $15.0 million. ...

NEWS RELEASE – February 24, 2026 Exhibit 99.1 Havertys Reports Operating Results for Fourth Quarter 2025 ATLANTA, GA / ACCESSWIRE / February 24, 2026 / HAVERTYS (NYSE: HVT) and (NYSE: HVT.A), today reported its operating results for the fourth quarter ended December 31, 2025. Fourth quarter 2025 versus fourth quarter 2024: FY 2025 versus FY 2024: Stock Repurchase Program: • The Board of Directors approved an additional $15 million authorization for the Company's stock repurchase program. Steven G. Burdette, ...

NEWS RELEASE – February 24, 2026 Exhibit 99.1 Havertys Reports Operating Results for Fourth Quarter 2025 ATLANTA, GA / ACCESSWIRE / February 24, 2026 / HAVERTYS (NYSE: HVT) and (NYSE: HVT.A), today reported its operating results for the fourth quarter ended December 31, 2025. Fourth quarter 2025 versus fourth quarter 2024: FY 2025 versus FY 2024: Stock Repurchase Program: • The Board of Directors approved an additional $15 million authorization for the Company's stock repurchase program. Steven G. Burdette, ...

Exhibit 99.1 (1) Same-store Hospitality excludes JW Marriott Desert Ridge, which was acquired June 10, 2025. ● The Company reported all-time quarterly record consolidated revenue of $737.8 million, driven by quarterly record same-store Hospitality (1) segment revenue of $578.2 million and record fourth quarter Entertainment segment revenue of $109.5 million. ● The Company generated fourth quarter net income of $74.5 million and consolidated Adjusted EBITDAre of $224.3 million. ● During the fourth quarter, t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36794 The Chemours Company (Exact Name of Registrant as Specified in Its Charter) (State or other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification N ...

Exhibit 99.1 FOR IMMEDIATE RELEASE ADAPTHEALTH CORP. ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS AND PROVIDES 2026 FINANCIAL GUIDANCE CONSHOHOCKEN, Pa. – February 24, 2026 - AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarte ...

Restaurant Operations and Growth - As of December 28, 2025, the company operated a total of 633 restaurants across 32 states, with 560 being company-owned and 73 franchise-owned[18]. - In 2025, the company opened 64 new system-wide restaurants across 23 states, continuing its growth strategy aimed at reaching over 2,200 potential locations in the U.S.[22]. - The company acquired 19 franchise-owned restaurants in 2025, enhancing its operational control and development rights in those territories[24]. - The average unit volume per restaurant is projected to be $2.3 million in 2025, achieved in only 7.5 hours of operation per day[17]. - As of December 28, 2025, First Watch had 9 franchisees operating 73 restaurants, with existing franchisees having 17 new restaurant development obligations[39]. Sales and Marketing - Off-premises sales accounted for 19.0% of total restaurant sales in 2025, up from 17.5% in 2024, indicating a growing trend in this segment[28]. - The company’s marketing programs and limited-time menu offerings may not meet expectations, impacting sales and profitability[82]. - Increased reliance on social media for marketing is essential, as traditional platforms may become obsolete, impacting brand relevance and customer engagement[108]. Employee Relations and Culture - The company has been recognized as a Top 100 Most Loved Workplace for four consecutive years, highlighting its strong employee culture[21]. - The company has a workforce of over 17,500 employees, with no collective bargaining agreements, fostering a favorable employee relationship environment[30]. - First Watch's employee turnover rates are significantly below the industry average, contributing to consistent and memorable dining experiences[50]. - The company operates on a "No Nights Ever" model, allowing employees to enjoy evenings with family and friends, enhancing work-life balance[42]. - The company has a robust training program, including a 10-week C.A.F.E. training for new managers and a new video-based training platform introduced in 2025[33]. - First Watch's beabetterhuman initiative includes monthly training workshops aimed at personal and professional development for employees[44]. Financial Performance and Risks - The company is vulnerable to changes in economic conditions and consumer preferences, which could materially affect its business and financial condition[68]. - Same-restaurant sales growth is critical for profitability, and the company may not achieve its targets due to unsuccessful marketing initiatives[80]. - The company experienced significant increases in food costs, particularly for eggs and coffee, due to external factors like avian influenza and climate conditions[83]. - The company relies on a small number of suppliers for a substantial amount of food and coffee, which poses risks related to supply shortages and cost increases[67]. - The financial performance of franchisees, which accounted for 12% of system-wide restaurants as of December 28, 2025, can materially affect the company's overall financial condition[97]. - The company may face challenges in maintaining good relationships with franchisees, which is crucial for revenue and market expansion[99]. - The company may incur additional costs to comply with new food safety requirements under the Food Safety Modernization Act, which could impact its operations[142]. Compliance and Legal Risks - The company is subject to compliance with various laws and regulations regarding nutritional disclosures, which could be costly and time-consuming[71]. - The company faces risks related to litigation over intellectual property, which could adversely affect sales and revenues if claims are decided against it[124]. - Compliance with evolving privacy and data protection laws is critical, as failure to adhere could lead to financial penalties and legal liabilities[114]. - The company may face increased operational costs due to new privacy laws, such as the California Consumer Privacy Act, which imposes stricter requirements on data handling[117]. Debt and Financial Structure - The principal amount of the company's term loans outstanding was $267.6 million as of December 28, 2025, which could significantly affect its business and financial condition[153]. - The company does not expect to pay dividends on its common stock for the foreseeable future, which may limit returns for investors[158]. - Future debt financing could involve restrictive covenants, making it more difficult for the company to obtain additional capital[166]. - The company may require additional capital to support business growth, which might not be available due to current market volatility affecting access to capital markets[171]. Operational Challenges - New restaurants typically experience lower operating profit margins during the first 12 months, and their performance may not meet historical averages due to various market factors[86]. - The company may face challenges in refinancing its debt or obtaining additional financing due to volatility in credit and capital markets[155]. - Labor shortages or increased costs due to competition or regulatory changes could adversely affect operating expenses and growth[133]. - The company operates under long-term non-cancelable leases, which could impact profitability if unable to negotiate favorable renewal terms[135].

Clinical Development - The company is developing risto-cel, an autologous HSC investigational therapy for sickle cell disease, with a Phase 1/2 clinical trial (BEACON) involving approximately 50 patients[657]. - Preliminary data from the BEACON trial showed mean HbF levels above 60% and a mean durable reduction in HbS below 40%[662]. - The company plans to submit a Biologics License Application (BLA) for risto-cel as early as year-end 2026[659]. - The company is conducting a Phase 1/2 clinical trial of BEAM-302 for alpha-1 antitrypsin deficiency (AATD), with updated clinical data expected in Q1 2026[663]. - BEAM-304 is a new liver-targeting LNP formulation for phenylketonuria (PKU), with plans to submit a regulatory application for a Phase 1/2 trial in 2026[665]. - The company is also developing BEAM-301 for glycogen storage disease Ia (GSDIa), with initial data from the trial expected in 2026[667]. - The median time to neutrophil engraftment in the BEACON trial was 17.5 days, with 29% of patients not requiring platelet transfusions post-treatment[662]. - The company has identified multiple targeted LNPs for in vivo delivery of gene editing payloads to HSCs, prioritizing this approach for sickle cell disease[660]. Financial Performance - License and collaboration revenue for the year ended December 31, 2025, was approximately $139.7 million, an increase of $76.2 million from $63.5 million in 2024[687]. - Research and development expenses increased to $409.6 million in 2025 from $367.6 million in 2024, reflecting a rise of $42.1 million[688]. - The accumulated deficit as of December 31, 2025, was $1.6 billion, with net losses of $80.0 million, $376.7 million, and $132.5 million for the years ended December 31, 2025, 2024, and 2023, respectively[675]. - The company expects to continue incurring significant operating losses as it advances its preclinical and clinical development activities[676]. - Total operating expenses for the year ended December 31, 2025, were $523.4 million, compared to $479.1 million in 2024, indicating an increase of $44.4 million[685]. - The company has not generated any revenue from product sales and does not expect to do so in the near future, relying primarily on license and collaboration agreements for revenue[678]. - The company anticipates that general and administrative expenses will increase to support research and development and compliance with public company requirements[683]. - The company recorded a gain of $255.1 million on the sale of an equity method investment during the year ended December 31, 2025[685]. - General and administrative expenses increased to $113.8 million in 2025 from $111.5 million in 2024, with a $27.9 million rise in external research and development expenses[690]. - The company recorded a net cash used in operating activities of $345.1 million for the year ended December 31, 2025, compared to $347.2 million in 2024[707][710]. - Cash used in investing activities for 2025 was $121.4 million, primarily due to net purchases of marketable securities totaling $367.3 million[712]. - Net cash provided by financing activities in 2025 was $478.0 million, largely from the issuance of common stock and pre-funded warrants, generating $470.5 million[714]. - The company had $1.2 billion in cash, cash equivalents, and marketable securities as of December 31, 2025[703]. - The company anticipates significant operating losses and expenses as it advances preclinical and clinical development of product candidates[698]. Financing and Obligations - The financing agreement includes a senior secured term loan facility of up to $500 million, with an initial draw of $100 million on February 24, 2026[668]. - The Credit Facility matures on February 24, 2033, and bears interest at an annual rate equal to the 3-month SOFR plus 6.50%[668]. - The Financing Agreement requires maintaining liquidity of at least $40 million, increasing to $80 million and $125 million upon drawing Delayed Draw A and B, respectively, if market capitalization is below $1.75 billion[671]. - The Financing Agreement includes a Credit Facility with an initial draw of $100 million and additional amounts available upon achieving certain milestones[704]. - The company may owe up to $90.0 million in success payments to Harvard and Broad Institute based on increases in the per share fair market value of its common stock[705]. - The company has potential obligations to pay up to an additional $90.0 million in success payments to Harvard and Broad Institute, payable in cash or shares of common stock[723]. - Future minimum commitments under noncancelable operating leases amount to $210.1 million as of December 31, 2025[722]. - The company may owe up to an additional $89.0 million in development, clinical, and commercial milestones to former stockholders of an acquired life sciences company[726]. Market and Economic Conditions - The company has cash, cash equivalents, and marketable securities totaling $1.2 billion as of December 31, 2025, with primary exposure to interest rate sensitivity[745]. - The company is not currently exposed to significant market risk related to foreign currency exchange rates but may increase exposure through future contracts with international vendors[746]. - Inflation has not materially affected the company's financial statements to date, but future operations may be adversely impacted[747]. - The company is required to make success payments based on increases in the per share fair market value of its common stock, which are accounted for as derivatives[741]. - The company has significant estimates and judgments related to accrued expenses and prepaid research and development costs, impacting financial statements[743]. - Revenue recognition is based on ASC 606, with revenue recognized when control of promised goods or services is obtained by the customer[730]. - The company has not recognized any milestone or royalty revenue from its agreements to date[738].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-4839948 (State or other jurisdict ...

Fourth Quarter 2025 Financial Highlights Exhibit 99.1 Xometry Reports Record Fourth Quarter and Strong Full Year 2025 Results NORTH BETHESDA, MD., February 24, 2026 /Globe Newswire/-- Xometry, Inc. (NASDAQ: XMTR), the global AI-native marketplace connecting buyers and suppliers of custom manufacturing, today announced its financial results for the fourth quarter and full year ended December 31, 2025. "Q4 was another record quarter, capping a transformative year for Xometry as enterprise customers rapidly ad ...